{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:25:27Z","timestamp":1761895527639},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,15]]},"DOI":"10.1097\/tp.0b013e318256dcba","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T10:02:26Z","timestamp":1342260146000},"page":"295-301","source":"Crossref","is-referenced-by-count":11,"title":["Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?"],"prefix":"10.1097","volume":"94","author":[{"given":"Pierre","family":"Peterlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Leux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Roland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Dubruille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Blin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Ayari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Clavert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Luc","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Wuilleme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":". Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":". The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":". Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":". Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":". Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":". Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":". Hyper-CVAD and high-dose methotrexatecytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"R10-14-20210129","first-page":"1275","article-title":". Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":". Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":". Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":". Comparison of 200 mgm(2) melphalan and 8 Gy total body irradiation plus 140 mgm(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial.","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":". High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":". High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience.","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","article-title":". Evaluation of the (R)VADC regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.","volume":"95","author":"Gressin","year":"2010","journal-title":"Haematologica"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":". Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":". Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score.","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":". Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":". Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":". High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":". Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":". Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation.","volume":"29","author":"Budde","year":"2011","journal-title":"J Clin Oncol"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":". Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis.","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":". A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":". Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2010.31.8006","article-title":". Indolent Mantle-Cell Lymphoma: Immunoglobulin Variable Region Heavy Chain Sequence Analysis Reveals Evidence of Disease 10 Years Prior to Symptomatic Clinical Presentation.","volume":"29","author":"Rule","year":"2011","journal-title":"J Clin Oncol"},{"key":"R31-14-20210129","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1200\/JCO.2010.29.8992","article-title":". Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.","volume":"28","author":"Christian","year":"2010","journal-title":"J Clin Oncol"},{"key":"R32-14-20210129","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":". Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.","volume":"115","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R33-14-20210129","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":". Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R34-14-20210129","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":". Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R35-14-20210129","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3109\/10428194.2010.496507","article-title":". Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.","volume":"51","author":"Dreyling","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R36-14-20210129","first-page":"1580","article-title":". High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma.","volume":"90","author":"Vigouroux","year":"2005","journal-title":"Haematologica"},{"key":"R37-14-20210129","first-page":"987","article-title":"The International Non-Hodgkins Lymphoma Prognostic Factors Project.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R38-14-20210129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":". A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"R39-14-20210129","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":". Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"R40-14-20210129","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":". Report of an international workshop to standardize response criteria for non-Hodgkins lymphomas. NCI Sponsored International Working Group.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e318256dcba","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:28:08Z","timestamp":1620977288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201208150-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318256dcba","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,15]]}}}